A comprehensive analysis of interventions designed to manage statin intolerance found minimal evidence of effectiveness. Examining 1,238 studies and analyzing data from nine eligible trials, researchers evaluated four main strategies: adjuvant therapies, dose titration, switching to alternative lipid-lowering medications, and changing statin types. The pooled analysis revealed risk ratios of 0.97 for randomized trials and 0.94 overall, with confidence intervals crossing 1.0, indicating no statistically significant benefit. This finding challenges common clinical practices used to address muscle pain, fatigue, and other side effects that lead up to 20% of patients to discontinue statins. The implications are significant given statins' proven cardiovascular benefits and the frequent clinical dilemma of managing intolerance. However, the analysis included only nine studies with moderate heterogeneity, limiting definitive conclusions. The research landscape remains fragmented, with most management strategies based on expert opinion rather than robust evidence. As this is a preprint awaiting peer review, these findings may be refined through the editorial process. The results suggest clinicians may need to reconsider current approaches to statin intolerance, though individual patient management should remain personalized pending stronger evidence.